Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
ONCY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Oncolytics Biotech Inc.NASDAQ: ONCY
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of CA$12.89M (cash outflow) rose 92.8% year over year, ahead of the +12.8% change in trailing-twelve-month net income. Sequentially, it rose 523.4% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -CA$32.62M (-17.3%) for the fiscal year ending Dec 2026, a slowdown from the +24.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$12.89M+523.4% QoQ
- Last fiscal yearDec 2025
- -CA$39.46M+24.4% YoY
- LTMMar 2026
- -CA$35.52M+12.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +92.8% | +37.2% | -55.6 pp |
| 1 year | +24.4% | -17.3% | -41.8 pp |
| 3-year CAGR | +16.7% | -19.8% | -36.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
CAD · from the cash flow
- Latest · FY2025
- (39.46M) CAD
- Year-over-year change
- -24.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.46M) | -24.4% |
| FY2024 | 2024-12-31 | (31.71M) | -14.3% |
| FY2023 | 2023-12-31 | (27.75M) | -11.7% |
| FY2022 | 2022-12-31 | (24.84M) | +5.6% |
| FY2021 | 2021-12-31 | (26.3M) | — |
Net Income vs competitors
How ONCY compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.8% is the 6th highest of 9, against a peer median of +19.3%.
- Over three fiscal years its annual growth of +16.7% compares with a peer median of -9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M USD | +319.3% | +88.7% | 4571.1% | |
| LTM Mar 2026 | $124.13M USD | -44.6% | -16.7% | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $47.38M USD | -39.3% | -31.6% | — | |
| LTM Mar 2026 | CA$35.52M CAD | +12.8% | +16.7% | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
| LTM Mar 2026 | $33.51M USD | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $21.13M USD | +23.3% | +20.1% | 266.1% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M USD | -67.7% | -30.2% | 288.3% |
| Peer median (excluding ONCY) | — | +19.3% | -9.5% | 288.3% | |
Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.3M) | (24.84M) | (27.75M) | (31.71M) | (39.46M) |
| Depreciation & Amortization | 452.07K | 392K | 403K | 424K | 96.05K |
| Deferred Income Tax | 408.56K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.83M | 2.38M | 2.07M | 2.72M | 4.26M |
| Change in Working Capital | (907.99K) | 391K | 1.77M | 3.54M | 1.62M |
| Accounts Receivables | (776.39K) | 345K | 506K | (53K) | 4.03M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (131.59K) | 46K | 1.26M | 3.59M | (2.41M) |
| Other Non-Cash Items | 91.73K | (1.68M) | (4.93M) | (1.94M) | 5.89M |
| Operating Cash Flow | (22.43M) | (23.36M) | (28.45M) | (26.97M) | (27.6M) |
| Capital Expenditures | (285.95K) | (55K) | (8K) | (239K) | (8.23K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.35M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 20.23M | 0 | 0 |
| Other Investing Activities | 0 | (20.35K) | 0 | 0 | 0 |
| Investing Cash Flow | (285.95K) | (20.4M) | 20.22M | (239K) | (8.23K) |
| Debt Repayment | (366K) | (381K) | (407K) | (348K) | 0 |
| Common Stock Issued | 32.91M | 12.57M | 31.62M | 6.92M | 19.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 469.68K | 12K | 781K | 65K | (37.05K) |
| Financing Cash Flow | 33.02M | 12.21M | 31.99M | 6.64M | 19.37M |
| Effect of Forex Changes | (253.25K) | 1.96M | (522K) | 1.6M | 166.03K |
| Net Change in Cash | 10.04M | (29.6M) | 23.25M | (18.97M) | (8.06M) |
| Free Cash Flow | (22.72M) | (23.41M) | (28.46M) | (27.21M) | (27.6M) |
Oncolytics Biotech Inc.
NASDAQ:ONCY
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.